IC50: 50 nM (IDO1), 3.0 μM (TrxR1)[1]
ZC0109 is a dual inhibitor of Arrested cell cycle at G1/S phase.
ZC0109 (15, 30, and 60 mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice[1].
ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice[1].
[1]. Zhou J, et al. Discovery of novel droxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114860.